Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site - Test2 - elhamkhani - TriplyDB

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

http://www.wikidata.org/entity/Q27319450

about

HIV Genome-Wide Protein Associations: a Review of 30 Years of Research HIV-Host Interactions: Implications for Vaccine Design Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection The HIV glycan shield as a target for broadly neutralizing antibodies Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site Survivors Remorse: antibody-mediated protection against HIV-1.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Discrete partitioning of HIV-1 Env forms revealed by viral capture.Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.Native-like Env trimers as a platform for HIV-1 vaccine design.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.Approaches to the induction of HIV broadly neutralizing antibodies.Evolution of B cell analysis and Env trimer redesign.Polyvalent vaccine approaches to combat HIV-1 diversity Identification and specificity of broadly neutralizing antibodies against HIV How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate.Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.

P2860

Q26746070-3E7F7751-A81C-4E7D-9773-A3053DEAD317 Q26765966-807DE137-7E4C-4147-952E-B88130F4FC64 Q26775082-DCEEE7AF-3B3F-4DFC-9439-A56BC5834693 Q26786540-259C4209-1D22-4B27-ACAC-1FF332DCBD92 Q27704710-89FDF713-66F4-4326-80FB-80227A497C66 Q27728037-8E33F3BD-4093-45AB-BDB2-E28783A727D4 Q30238730-DD6FEF77-C6CD-4F0F-875A-0140C9D6082F Q33612459-F99CFFE1-7E02-4AC4-AFA0-68B7DDE735FF Q33711154-A479C689-2205-4E6B-8D8B-8C66EBB85A16 Q33753573-FC772F08-F93B-4D13-BD50-1D9375664718 Q33907694-AFE6CF5F-6D46-4000-8A7D-EEC290DE012C Q36086357-A80D6C9E-CF89-42A9-AF54-7A0D5773FE57 Q36088254-EFE200FD-91D2-444D-9119-EAD6D05D4299 Q36112751-25EBCDFF-0182-4ED1-9AE6-83D3ACB21E33 Q36132706-843F7D04-CE1C-4677-B4BC-67A8F744F622 Q36194234-3B09D6DC-2434-4ACC-8313-721A572E4E0F Q36239578-23111D64-9A35-420E-9F4B-747129513458 Q36263513-38DD5045-41B6-49A6-B467-1ED87A3183DF Q36303368-5B5C1094-97A5-4EA9-A247-7DF325F2B661 Q36434196-50B9EF98-BA9E-4576-8348-5213D01B338B Q36811996-6AB3E818-A8A7-4619-BC13-3AF787C2994F Q37060947-09131CF7-9FAB-4729-A3F6-53BEEB4BBF1C Q37252966-BF441021-2696-4F2F-A825-5963FF38AD21 Q37409244-05CEEED1-BD1B-48FF-BCB6-AB3B6E7135E4 Q37633417-4A483987-E8EB-4DD6-903D-3749D1E053C7 Q38665463-B6F04D55-E3D2-4D82-B213-7ADA19A9F773 Q38708708-34112418-1FB1-4FB1-8FCD-D7C0E8F72728 Q38753943-13CA2235-6C42-401C-AA4B-38984A14F1F4 Q38936867-3238DDBB-5108-4C1F-84A7-397A1A05B62D Q38992740-13F750BC-7FBB-4F5F-9D0A-94D149A38840 Q39108740-4C643F32-4E33-4055-B457-C73DA1E7AC5E Q39108796-8E86E664-ABA9-46E3-9E49-1575AE4B48D8 Q39250593-6C2682A5-444F-4694-A807-6DCDDAD7A30E Q40043429-35498E7E-1B15-485E-B503-434972CB7D34 Q40073016-AE3F5A5E-1BD7-4FDB-8577-B9894AE06411 Q40198060-49CBBF3D-B48A-4F1C-B26C-07103385E98E Q40220988-6B70AD7A-B52F-4EFE-98C5-3FB49A08A697 Q40226810-2F02C580-CB24-445D-BB8D-746F203D2EF2 Q40406623-2A4152CA-1EC7-4837-834F-2F3DC3654D0D Q40442031-014FF811-497C-4062-AE16-989821AD7534

P2860

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

http://www.wikidata.org/entity/Q27319450

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@ast

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@en

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@nl

type

label

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@ast

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@en

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@nl

prefLabel

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@ast

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@en

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@nl

P1433

Q27319450-6628BD1E-7B8C-401F-8DAB-D78AF469CEB5

P1476

Q27319450-33FF5EE7-0C8D-4CCF-9899-A0B6B70CF495

P2093

Q27319450-02BD4234-D049-4674-8653-D48F0813DC35

Q27319450-0DE4629B-1885-4305-BB87-5AD0BFE48FFA

Q27319450-111C47DF-9AEA-4F0A-9655-C4F501C3CAD3

Q27319450-14AA573E-713D-4A66-86D1-AEAF69AFB769

Q27319450-1DE55BAE-2AA8-4270-B129-7681D4071116

Q27319450-311AD39B-9AEF-45F0-8301-F3BD1BAFE42E

Q27319450-3A6249C8-4234-4EC5-B04C-806CED5BF0E0

Q27319450-66E5EB7F-E6A5-4FD0-B69E-7B6A0BD9210A

Q27319450-7A641881-4B70-4179-91FD-8CFD15899F9E

Q27319450-814A63C4-507F-4C6F-A504-8051998009C8

P2860

Q27319450-015F53E8-BEB8-4C34-ABC0-76EE878BB7D6

Q27319450-02A63082-3C16-47EF-B030-BC58201D54BD

Q27319450-0FE06EF7-0CA0-4DC0-B94A-39B1B1689426

Q27319450-1088C241-56F3-4372-9F94-EB25AD2BCC1A

Q27319450-16F5DA12-A7C3-4CE4-8F77-46A6EBC17476

Q27319450-18A84B4D-3744-469D-9571-1FE5FB1C0CE6

Q27319450-19A94DF0-A5D0-4A52-B24A-BF8AEC63DE3A

Q27319450-1B1B6DD7-3ADB-4641-9649-D86A9C10B561

Q27319450-1B4D5446-0EA8-402C-B023-3B71B749DED1

Q27319450-1DB62DBF-548B-4021-89E6-FF2581F5E5A8

P304

Q27319450-566F7563-A4F4-45EA-8B2B-3159AE460734

P31

Q27319450-B0E900F5-6BB1-41C4-94C5-78C09A211CEE

P3181

Q27319450-5949EDE0-3951-4866-BD98-74E40F9BC690

P356

Q27319450-EE5C4A4B-60B2-49AD-BEE7-C0F9D1DFBDC9

P407

Q27319450-3B70C9F3-22F5-448F-A136-99C0B38F6B27

P433

Q27319450-4BE3D640-C53F-41EE-87FD-A272EC2CC3A4

P478

Q27319450-C59B8A04-5F8D-4E72-B8C5-3164DB1316A5

P50

Q27319450-5DBB45F6-0B74-4BF4-8834-EACB05EA5BAE

Q27319450-90744A5A-30B1-4116-A3E0-3A86A47BF810

Q27319450-948B949E-AB32-4F11-9AB0-4BCDAF110C32

P577

Q27319450-752075C0-1B84-447F-8429-263C5E024659

P5875

Q27319450-019CCE78-E5F8-4532-80EC-0EE79E542260

P698

Q27319450-1CCF97EF-04CC-462E-B339-2CBE7B24A5D0

P921

Q27319450-DFDAF191-E116-4B74-8B12-0E2FAFA2B930

Q27319450-FD7E7D47-CB2F-4735-A36A-B9EA2AAE7D70

P932

Q27319450-BFA68365-F135-45D5-B1FD-52E7D8BB0CE2

P3181

P356

JOURNAL.PPAT.1004932

P1433

P1476

Vaccine-Elicited Tier 2 HIV-1 ...... oximal to the CD4 Binding Site

@en

P2093

Bimal Chakrabarti

http://www.w3.org/2001/XMLSchema#string

Celia LaBranche

http://www.w3.org/2001/XMLSchema#string

Daniel Kulp

http://www.w3.org/2001/XMLSchema#string

Ema T Crooks

http://www.w3.org/2001/XMLSchema#string

Ivelin S Georgiev

http://www.w3.org/2001/XMLSchema#string

James E Robinson

http://www.w3.org/2001/XMLSchema#string

James M Binley

http://www.w3.org/2001/XMLSchema#string

Janelle Muranaka

http://www.w3.org/2001/XMLSchema#string

Joanne Destefano

http://www.w3.org/2001/XMLSchema#string

Keiko Osawa

http://www.w3.org/2001/XMLSchema#string

P2860

Jalview Version 2--a multiple sequence alignment editor and analysis workbench

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth

Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans

P304

e1004932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

445789

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.1004932

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Guillaume Stewart-Jones

David C Montefiori

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277407063

http://www.w3.org/2001/XMLSchema#string

P698

26023780

http://www.w3.org/2001/XMLSchema#string

P921

P932

4449185

http://www.w3.org/2001/XMLSchema#string